SK Biopharmaceuticals Inks Research Collaboration Agreement with ProEn Therapeutics Further Accelerating Expansion of Oncology Research and Pipeline for Global Competitiveness in Radiopharmaceuticals
SK Biopharmaceuticals,ProEn Therapeutics aim to advance up to 2 preclinical radiopharmaceutical candidates by 2027,via ArtBody™,a bivalent binder platform designed to selectively target tumor cells